Sunday, October 4, 2026

USD/EUR Over 1% Down In The Last 21 Sessions

USD/EUR Over 1% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.74% for the last 21 sessions. At 15:10 EST on Monday, 27 March, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 3.556% up from its 52-week low and 11.658% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a negative 0.13%, and a positive 0.47%, respectively.

USD/EUR's highest amplitude of average volatility was 0.53% (last week), 0.55% (last month), and 0.47% (last quarter), respectively.

News about

  • Usd/jpy climbs to fresh daily high, around mid-131.00s amid receding safe-haven demand. According to FXStreet on Monday, 27 March, "A generally positive tone around the equity markets undermines the safe-haven Japanese Yen (JPY), which, in turn, is seen as a key factor acting as a tailwind for the USD/JPY pair. ", "Apart from this, expectations that the Bank of Japan (BoJ) will tweak its bond yield control policy and whittle down its massive stimulus under new Governor Kazuo Ueda might contribute to capping gains for the USD/JPY pair. "
  • Usd/jpy: neutral view amidst global banking turmoil – morgan stanley. According to FXStreet on Monday, 27 March, "Analysts at Morgan Stanley shift their view on the USD/JPY pair to neutral from their previous long recommendation.", "With the risk of the market pricing in further policy convergence, we close our long USD/JPY position and turn neutral until things become much clearer."
  • Usd/jpy price analysis: bulls find support at 130.00 amid banking support measures. According to FXStreet on Monday, 27 March, "The USD/JPY experienced a sharp rebound after finding support at the 130.00 mark. ", "The fundamental picture for the USD/JPY portrays a downside bias, but the Relative Strength Index (RSI) signals a possible pullback due to slightly oversold conditions."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Citigroup Inc.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com